Annexin Pharmaceuticals AB (publ) (ANNX.ST)
SEK 0.27
(4.62%)
SEK 0.27
(4.62%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 44.17 Million SEK | 8.66% |
| 2022 | 40.65 Million SEK | -23.04% |
| 2021 | 52.82 Million SEK | 18.39% |
| 2020 | 44.62 Million SEK | 58.8% |
| 2019 | 28.1 Million SEK | -0.93% |
| 2018 | 28.36 Million SEK | -6.63% |
| 2017 | 30.38 Million SEK | 210.54% |
| 2016 | 9.78 Million SEK | 94.65% |
| 2015 | 5.02 Million SEK | 399.19% |
| 2014 | 1 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 12.45 Million SEK | -16.09% |
| 2024 Q2 | 14.44 Million SEK | 15.97% |
| 2024 Q3 | 10.92 Million SEK | -24.35% |
| 2023 Q3 | 10.67 Million SEK | 26.43% |
| 2023 Q2 | 8.44 Million SEK | -16.43% |
| 2023 FY | 43.84 Million SEK | 7.85% |
| 2023 Q1 | 10.1 Million SEK | 0.49% |
| 2023 Q4 | 14.84 Million SEK | 39.1% |
| 2022 Q2 | 11.19 Million SEK | 18.49% |
| 2022 Q1 | 9.44 Million SEK | -39.57% |
| 2022 Q4 | 10.05 Million SEK | 4.24% |
| 2022 Q3 | 9.64 Million SEK | -13.85% |
| 2022 FY | 40.65 Million SEK | -23.04% |
| 2021 Q1 | 19.05 Million SEK | 11.72% |
| 2021 Q2 | 10.19 Million SEK | -46.49% |
| 2021 Q4 | 15.63 Million SEK | 91.19% |
| 2021 FY | 52.82 Million SEK | 18.39% |
| 2021 Q3 | 8.17 Million SEK | -19.81% |
| 2020 Q3 | 8.38 Million SEK | -28.39% |
| 2020 Q4 | 17.05 Million SEK | 103.4% |
| 2020 Q1 | 7.57 Million SEK | -25.17% |
| 2020 FY | 44.62 Million SEK | 58.8% |
| 2020 Q2 | 11.71 Million SEK | 54.59% |
| 2019 Q3 | 6.46 Million SEK | 8.1% |
| 2019 FY | 28.1 Million SEK | -0.93% |
| 2019 Q4 | 10.12 Million SEK | 56.67% |
| 2019 Q2 | 5.97 Million SEK | 7.98% |
| 2019 Q1 | 5.53 Million SEK | -20.06% |
| 2018 Q2 | 7.56 Million SEK | -15.73% |
| 2018 Q1 | 8.97 Million SEK | -1.0% |
| 2018 Q3 | 4.81 Million SEK | -36.26% |
| 2018 Q4 | 6.92 Million SEK | 43.7% |
| 2018 FY | 28.36 Million SEK | -6.63% |
| 2017 Q1 | 7.3 Million SEK | 106.85% |
| 2017 FY | 30.38 Million SEK | 210.54% |
| 2017 Q2 | 10.02 Million SEK | 37.22% |
| 2017 Q3 | 3.76 Million SEK | -62.46% |
| 2017 Q4 | 9.06 Million SEK | 140.69% |
| 2016 Q2 | 867 Thousand SEK | 41.21% |
| 2016 Q1 | 614 Thousand SEK | 0.0% |
| 2016 FY | 9.78 Million SEK | 94.65% |
| 2016 Q4 | 3.53 Million SEK | -25.82% |
| 2016 Q3 | 4.76 Million SEK | 449.37% |
| 2015 FY | 5.02 Million SEK | 399.19% |
| 2014 FY | 1 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Active Biotech AB (publ) | 44.8 Million SEK | 1.413% |
| Amniotics AB (publ) | 29.07 Million SEK | -51.954% |
| BioArctic AB (publ) | 89.62 Million SEK | 50.711% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 97.083% |
| Camurus AB (publ) | 1.05 Billion SEK | 95.831% |
| Cantargia AB (publ) | 290.01 Million SEK | 84.768% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -101.763% |
| CombiGene AB (publ) | 44.14 Million SEK | -0.072% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 69.105% |
| Genovis AB (publ.) | 88.19 Million SEK | 49.912% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 61.61% |
| Mendus AB (publ) | 129.13 Million SEK | 65.791% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -507.815% |
| Intervacc AB (publ) | 79.78 Million SEK | 44.631% |
| Kancera AB (publ) | 63.07 Million SEK | 29.965% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -700.435% |
| LIDDS AB (publ) | 27.75 Million SEK | -59.181% |
| Lipum AB (publ) | 37.3 Million SEK | -18.412% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -508.988% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 67.497% |
| NextCell Pharma AB | -576.01 Thousand SEK | 7769.191% |
| OncoZenge AB (publ) | 15.9 Million SEK | -177.749% |
| Saniona AB (publ) | 1.07 Million SEK | -4001.764% |
| Simris Alg AB (publ) | 38.64 Million SEK | -14.321% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 86.26% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 87.647% |
| Xintela AB (publ) | 57.31 Million SEK | 22.926% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 75.692% |
| Ziccum AB (publ) | 27.87 Million SEK | -58.462% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -201.481% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -55.954% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -169.349% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 85.615% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -3.622% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -149.822% |
| Corline Biomedical AB | 30.16 Million SEK | -46.433% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 23.875% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 46.884% |
| Aptahem AB (publ) | 10.01 Million SEK | -341.189% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 67.203% |
| Fluicell AB (publ) | 28.61 Million SEK | -54.37% |
| Biovica International AB (publ) | 133.72 Million SEK | 66.964% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -123.224% |
| AcouSort AB (publ) | 25.87 Million SEK | -70.722% |
| Abliva AB (publ) | 27.86 Million SEK | -58.53% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 77.17% |
| 2cureX AB (publ) | 36.51 Million SEK | -20.97% |
| I-Tech AB | 40.14 Million SEK | -10.033% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 94.86% |
| Cyxone AB (publ) | 28.21 Million SEK | -56.575% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 59.608% |
| Biosergen AB | 26.8 Million SEK | -64.78% |
| Nanologica AB (publ) | 69.88 Million SEK | 36.789% |
| SynAct Pharma AB | 224.49 Million SEK | 80.322% |
| BioInvent International AB (publ) | 441.4 Million SEK | 89.992% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -84.418% |
| Alzinova AB (publ) | 36.39 Million SEK | -21.376% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 84.754% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -462.303% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 60.171% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -200.517% |